Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo.

PloS one - 1 Jan 2012

Bobrowska Anna, Donmez Gizem, Weiss Andreas, Guarente Leonard, Bates Gillian

Abstract excerpt

Huntington's disease (HD) is a devastating neurodegenerative disorder for which there are no disease-modifying treatments. The molecular pathogenesis of HD is complex and many mechanisms and cellular processes have been proposed as potential sites of therapeutic intervention. However, prior to embarking on drug development initiatives, it is essential that therapeutic targets can be validated in mammalian models...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Brain
Share to Cholesterol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Huntington Disease

Share to Mice, Knockout

Share to Sirtuin 2

Share to Tubulin

Source

Open in PubMed Open full text

Identifiers

PMID: 22511966
DOI: 10.1371/journal.pone.0034805
PMCID: PMC3325254

Genes

SIRT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo.PMID 22511966Read ↗

The Sirtuin 2 Inhibitor AK-7 Is Neuroprotective in Huntington’s Disease Mouse ModelsSemantic proximity Read ↗

A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's diseaseSemantic proximity Read ↗

Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s diseaseSemantic proximity Read ↗

Sirtuins: double players in Huntington's diseaseSemantic proximity Read ↗

Evaluation of Histone Deacetylases as Drug Targets in Huntington’s Disease modelsStudy of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model.Semantic proximity Read ↗

Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease.Semantic proximity Read ↗

Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.Semantic proximity Read ↗

Sirtuins as Modifiers of Huntington's Disease (HD) Pathology.Semantic proximity Read ↗

SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice.Semantic proximity Read ↗

The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNSSemantic proximity Read ↗

SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.Semantic proximity Read ↗

Targeting sirtuin-1 in Huntington's disease: rationale and current status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.